Founded: 2002
Officers: Lois Moran, President, CEO; Lynn Macrone, Partner, Chief Creative Officer; Forrest King, Partner, Chief Innovation Officer; Roxana Bannach-Lin, EVP, Strategic Planning/Business Development; Colleen Katzman, EVP, Managing Director, Account Services; Adam Kline, SVP, Group Creative Director, Art; Randy Goldstein, SVP, Creative Support Services; Howard Nagelberg, Chief Financial Officer; Robert Palmer, EVP, Digital Practice; Laurence Richards, EVP, Managing Director, Account Services; Joan Wildermuth, SVP, Group Creative Director, Copy
2010 Gross Income: $25 million to $40 million
Full-time Employees: 126 (2010) 100 (2009)
Healthcare accounts: Leo Pharma: PEP005; Merck & Co., Inc.: Afluria, Asmanex, Gardasil, Maxalt, Nasonex, Pneumovax 23, Preladenant, Recombivax HB, Saflutan, Saphris, Singulair Allergic Rhinitis, Singulair Asthma, Suvorexant, Telcagepant, Vaqta, Zostavax; Pfizer: Benefix, ReFacto AF, Tofacitinib, Xyntha
Number of Accounts gained: 5
Accounts gained: Leo Pharma: PEP005; Merck & Co., Inc.: Asmanex, Nasonex, Saphris; Pfizer: Tofacitinib.
Services: JUICE Pharma Worldwide based in New York City, is a creative-strategic “bigtique” advertising agency that provides highly disciplined, evidence-based solutions for professional and patient audiences for pharmaceutical clients around the world. JUICE Pharma offers capabilities in five core areas: Creative-strategic support throughout the life cycle of the brand, global brand stewardship, multiple-channel marketing, Medical Strategy, and customer-centric solutions-based offerings. Focused on innovation, JUICE Pharma works to integrate the latest wave of emerging technology to cover the complete spectrum of solutions, from traditional print to web-based new media and digital selling platforms. JUICE Pharma’s founding partners include Lois Moran, Lynn Macrone, and Forrest King.
Featured Work
Product: PNEUMOVAX 23
Client: : Merck
Why this ad is special: The PNEUMOVAX 23 was developed to protect the broad range of patients who are at increased risk for the disease against range of pneumococcal serotypes that cause the disease.